Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Immunoglobulin Light-chain Amyloidosis 2Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2330Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1782Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 935Prednisone 925Cetuximab 921Lenalidomide 916Trastuzumab 901

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × 4'-deoxy-4'-iododoxorubicin × Clear all
NCT00030381 2013-01-16

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

National Cancer Institute (NCI)

Phase 1 Terminated
22 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT00003853 2012-11-12

4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis

National Cancer Institute (NCI)

Phase 2 Completed
45 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡